Md. Hurwitz et al., Feasibility and patient tolerance of a novel transrectal ultrasound hyperthermia system for treatment of prostate cancer, INT J HYPER, 17(1), 2001, pp. 31-37
This report describes patient tolerance and toxicity of a transrectal ultra
sound hyperthermia system used with external beam radiation therapy in trea
tment of locally advanced prostate cancer. Nine patients with clinical T2B-
T3B (4(th) edition AJCC criteria) disease received external beam radiation
therapy, with two hyperthermia treatments scheduled at least 1 week apart d
uring the first 4 weeks of radiation. Five patients also received hormonal
therapy. Interstitial and anterior rectal wall thermometry were performed.
Median temperature for each treatment (T-50) was 40.8 degreesC and mean CEM
T-90=43 degreesC was 3.4 min. Rectal wall temperature was maintained at le
ss than or equal to 40 degreesC. Treatment duration was limited in three of
17 sessions due to positional discomfort which was alleviated with light I
V sedation and use of a 'New Life' mattress (Comfortex, Inc. Winoba, MN, US
A). Acute toxicity was limited to NCl common toxicity criteria grade 1 and
no excess toxicity was noted with full course radiation therapy +/- hormona
l therapy. These findings are consistent with those reported in a previous
phase I trial assessing this device. Given the favourable toxicity profile
demonstrated to date, modification of treatment parameters for this ongoing
phase II study have been instituted that should further the efficacy of tr
ansrectal ultrasound hyperthermia for treatment of prostate cancer.